Trade Rain Therapeutics Inc. - RAIN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Rain Oncology Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.06 |
Open* | 1.04 |
1-Year Change* | -86.73% |
Day's Range* | 1.04 - 1.05 |
52 wk Range | 0.82-14.48 |
Average Volume (10 days) | 145.67K |
Average Volume (3 months) | 3.75M |
Market Cap | 38.92M |
P/E Ratio | -100.00K |
Shares Outstanding | 36.38M |
Revenue | N/A |
EPS | -2.07 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 27, 2023 | 1.06 | -0.02 | -1.85% | 1.08 | 1.08 | 1.06 |
Nov 24, 2023 | 1.07 | 0.05 | 4.90% | 1.02 | 1.07 | 1.02 |
Nov 22, 2023 | 1.04 | -0.01 | -0.95% | 1.05 | 1.05 | 1.03 |
Nov 21, 2023 | 1.05 | -0.01 | -0.94% | 1.06 | 1.06 | 1.03 |
Nov 20, 2023 | 1.06 | 0.00 | 0.00% | 1.06 | 1.07 | 1.03 |
Nov 17, 2023 | 1.07 | 0.03 | 2.88% | 1.04 | 1.07 | 1.00 |
Nov 16, 2023 | 1.02 | -0.07 | -6.42% | 1.09 | 1.09 | 1.02 |
Nov 15, 2023 | 1.09 | 0.00 | 0.00% | 1.09 | 1.10 | 1.08 |
Nov 14, 2023 | 1.07 | -0.04 | -3.60% | 1.11 | 1.12 | 1.06 |
Nov 13, 2023 | 1.08 | 0.05 | 4.85% | 1.03 | 1.11 | 1.02 |
Nov 10, 2023 | 1.05 | 0.07 | 7.14% | 0.98 | 1.08 | 0.98 |
Nov 9, 2023 | 1.00 | -0.05 | -4.76% | 1.05 | 1.09 | 0.97 |
Nov 8, 2023 | 1.08 | 0.04 | 3.85% | 1.04 | 1.10 | 1.04 |
Nov 7, 2023 | 1.09 | 0.01 | 0.93% | 1.08 | 1.09 | 1.07 |
Nov 6, 2023 | 1.09 | 0.03 | 2.83% | 1.06 | 1.10 | 1.06 |
Nov 3, 2023 | 1.10 | 0.02 | 1.85% | 1.08 | 1.10 | 1.06 |
Nov 2, 2023 | 1.08 | 0.04 | 3.85% | 1.04 | 1.10 | 1.04 |
Nov 1, 2023 | 1.06 | 0.03 | 2.91% | 1.03 | 1.07 | 1.02 |
Oct 31, 2023 | 1.05 | 0.03 | 2.94% | 1.02 | 1.05 | 1.02 |
Oct 30, 2023 | 1.04 | -0.02 | -1.89% | 1.06 | 1.06 | 1.03 |
Rain Therapeutics Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 7, 2024 | ||
Time (UTC) 21:00 | Country US
| Event Q4 2023 Rain Oncology Inc Earnings Release Q4 2023 Rain Oncology Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 |
Total Operating Expense | 77.136 | 51.512 | 18.958 | 10.828 |
Selling/General/Admin. Expenses, Total | 15.736 | 10.739 | 3.591 | 3.538 |
Research & Development | 61.4 | 40.773 | 10.2 | 7.29 |
Unusual Expense (Income) | 5.167 | 0 | ||
Operating Income | -77.136 | -51.512 | -18.958 | -10.828 |
Interest Income (Expense), Net Non-Operating | 1.415 | 0.119 | -0.103 | 0.177 |
Other, Net | -0.001 | -2.022 | -0.251 | |
Net Income Before Taxes | -75.721 | -51.394 | -21.083 | -10.902 |
Net Income After Taxes | -75.724 | -51.392 | -21.083 | -10.902 |
Net Income Before Extra. Items | -75.724 | -51.392 | -21.083 | -10.902 |
Net Income | -75.724 | -51.392 | -21.083 | -10.902 |
Income Available to Common Excl. Extra. Items | -75.724 | -51.394 | -21.083 | -10.902 |
Income Available to Common Incl. Extra. Items | -75.724 | -51.394 | -21.083 | -10.902 |
Diluted Net Income | -75.724 | -51.394 | -21.083 | -10.902 |
Diluted Weighted Average Shares | 27.9855 | 19.4058 | 25.9692 | 25.9692 |
Diluted EPS Excluding Extraordinary Items | -2.70584 | -2.64838 | -0.81185 | -0.41981 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -2.70584 | -2.64838 | -0.61288 | -0.41981 |
Total Adjustments to Net Income | -0.002 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 23.231 | 21.743 | 23.557 | 18.411 | 17.718 |
Selling/General/Admin. Expenses, Total | 5.414 | 5.066 | 4.479 | 3.901 | 3.461 |
Research & Development | 14.98 | 16.677 | 19.078 | 14.51 | 14.257 |
Operating Income | -23.231 | -21.743 | -23.557 | -18.411 | -17.718 |
Interest Income (Expense), Net Non-Operating | 1.167 | 1.259 | 0.882 | 0.37 | 0.107 |
Net Income Before Taxes | -22.064 | -20.484 | -22.675 | -18.041 | -17.611 |
Net Income After Taxes | -22.064 | -20.484 | -22.678 | -18.041 | -17.611 |
Net Income Before Extra. Items | -22.064 | -20.484 | -22.678 | -18.041 | -17.611 |
Net Income | -22.064 | -20.484 | -22.678 | -18.041 | -17.611 |
Income Available to Common Excl. Extra. Items | -22.064 | -20.484 | -22.678 | -18.041 | -17.611 |
Income Available to Common Incl. Extra. Items | -22.064 | -20.484 | -22.678 | -18.041 | -17.611 |
Diluted Net Income | -22.064 | -20.484 | -22.678 | -18.041 | -17.611 |
Diluted Weighted Average Shares | 36.3633 | 36.3399 | 32.3354 | 26.5646 | 26.5295 |
Diluted EPS Excluding Extraordinary Items | -0.60677 | -0.56368 | -0.70134 | -0.67914 | -0.66383 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -0.52875 | -0.56368 | -0.70134 | -0.67914 | -0.66383 |
Other, Net | 0 | ||||
Unusual Expense (Income) | 2.837 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total Current Assets | 133.628 | 146.146 | 59.525 | 6.274 |
Cash and Short Term Investments | 130.454 | 140.218 | 58.863 | 5.794 |
Cash & Equivalents | 61.955 | 24.78 | 58.863 | 5.794 |
Prepaid Expenses | 2.432 | 5.252 | 0.53 | 0.37 |
Other Current Assets, Total | 0.742 | 0.676 | 0.132 | 0.11 |
Total Assets | 135.18 | 147.14 | 61.08 | 7.395 |
Property/Plant/Equipment, Total - Net | 0.351 | 0.551 | 0.546 | 0.692 |
Property/Plant/Equipment, Total - Gross | 0.587 | 0.707 | 0.631 | 0.725 |
Accumulated Depreciation, Total | -0.236 | -0.156 | -0.085 | -0.033 |
Note Receivable - Long Term | 0.052 | 0.298 | 0.549 | 0.354 |
Other Long Term Assets, Total | 1.149 | 0.145 | 0.46 | 0.075 |
Total Current Liabilities | 21.966 | 16.315 | 3.419 | 1.224 |
Accounts Payable | 7.146 | 6.112 | 0.816 | 0.261 |
Accrued Expenses | 14.82 | 10.203 | 1.076 | 0.684 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.527 | 0.279 | ||
Total Liabilities | 22.144 | 16.636 | 3.8 | 4.496 |
Total Long Term Debt | 0 | 0 | 0 | 2.751 |
Long Term Debt | 0 | 2.751 | ||
Other Liabilities, Total | 0.178 | 0.321 | 0.381 | 0.521 |
Total Equity | 113.036 | 130.504 | 57.28 | 2.899 |
Redeemable Preferred Stock | 0 | 0 | 95.024 | 20.147 |
Common Stock | 0.037 | 0.027 | 0.004 | 0.003 |
Additional Paid-In Capital | 278.853 | 220.53 | 1.149 | 0.236 |
Retained Earnings (Accumulated Deficit) | -165.688 | -89.964 | -38.57 | -17.487 |
Total Liabilities & Shareholders’ Equity | 135.18 | 147.14 | 61.08 | 7.395 |
Total Common Shares Outstanding | 36.2903 | 26.4758 | 25.9692 | 25.9692 |
Preferred Stock - Non Redeemable, Net | -0.327 | |||
Short Term Investments | 68.499 | 115.438 | ||
Other Equity, Total | -0.166 | -0.089 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 80.816 | 90.993 | 112.975 | 133.628 | 93.745 |
Cash and Short Term Investments | 77.32 | 86.29 | 109.77 | 130.454 | 90.708 |
Cash & Equivalents | 37.312 | 40.076 | 44.1 | 61.955 | 39.834 |
Prepaid Expenses | 2.665 | 3.969 | 2.502 | 2.432 | 2.615 |
Total Assets | 82.06 | 91.723 | 114.178 | 135.18 | 94.635 |
Property/Plant/Equipment, Total - Net | 1.064 | 0.55 | 0.299 | 0.351 | 0.394 |
Other Long Term Assets, Total | 0.18 | 0.18 | 0.851 | 1.149 | 0.443 |
Total Current Liabilities | 14.477 | 18.331 | 19.48 | 21.966 | 13.013 |
Accounts Payable | 8.973 | 5.801 | 7.421 | 7.146 | 4.084 |
Accrued Expenses | 5.504 | 12.53 | 12.059 | 14.82 | 8.929 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14.541 | 18.434 | 19.621 | 22.144 | 13.226 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.064 | 0.103 | 0.141 | 0.178 | 0.213 |
Total Equity | 67.519 | 73.289 | 94.557 | 113.036 | 81.409 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.037 | 0.037 | 0.037 | 0.037 | 0.027 |
Additional Paid-In Capital | 282.816 | 281.588 | 280.739 | 278.853 | 224.694 |
Retained Earnings (Accumulated Deficit) | -215.27 | -208.236 | -186.172 | -165.688 | -143.01 |
Total Liabilities & Shareholders’ Equity | 82.06 | 91.723 | 114.178 | 135.18 | 94.635 |
Total Common Shares Outstanding | 36.3757 | 36.3757 | 36.3632 | 36.2903 | 26.5648 |
Short Term Investments | 40.008 | 46.214 | 65.67 | 68.499 | 50.874 |
Other Equity, Total | -0.064 | -0.1 | -0.047 | -0.166 | -0.302 |
Note Receivable - Long Term | 0 | 0.053 | 0.052 | 0.053 | |
Other Current Assets, Total | 0.831 | 0.734 | 0.703 | 0.742 | 0.422 |
Property/Plant/Equipment, Total - Gross | 1.489 | 0.821 | 0.553 | 0.587 | 0.612 |
Accumulated Depreciation, Total | -0.425 | -0.271 | -0.254 | -0.236 | -0.218 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Net income/Starting Line | -75.724 | -51.394 | -21.083 | -10.902 |
Cash From Operating Activities | -63.199 | -37.463 | -11.231 | -11.182 |
Cash From Operating Activities | 0.08 | 0.071 | 0.052 | 0.028 |
Non-Cash Items | 3.515 | 8.672 | 8.191 | 0.519 |
Changes in Working Capital | 8.93 | 5.188 | 1.609 | -0.827 |
Cash From Investing Activities | 47.194 | -118.235 | -5.191 | -0.144 |
Capital Expenditures | -0.008 | -0.128 | -0.024 | -0.144 |
Other Investing Cash Flow Items, Total | 47.202 | -118.107 | -5.167 | 0 |
Cash From Financing Activities | 53.18 | 121.615 | 69.491 | 2.5 |
Financing Cash Flow Items | -3.467 | -11.872 | -0.166 | 0 |
Issuance (Retirement) of Stock, Net | 56.647 | 133.487 | 63.222 | 0 |
Issuance (Retirement) of Debt, Net | 0 | 6.435 | 2.5 | |
Net Change in Cash | 37.175 | -34.083 | 53.069 | -8.826 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -20.484 | -75.724 | -53.046 | -35.005 | -17.394 |
Cash From Operating Activities | -21.839 | -63.199 | -49.905 | -34.542 | -17.11 |
Cash From Operating Activities | 0.018 | 0.08 | 0.062 | 0.044 | 0.022 |
Non-Cash Items | 0.998 | 3.515 | 2.556 | 2.709 | 1.275 |
Changes in Working Capital | -2.371 | 8.93 | 0.523 | -2.29 | -1.013 |
Cash From Investing Activities | 3.518 | 47.194 | 64.386 | 52.76 | 13.436 |
Capital Expenditures | -0.008 | 0 | 0 | 0 | |
Cash From Financing Activities | 0.466 | 53.18 | 0.573 | 0.411 | 0.399 |
Financing Cash Flow Items | -0.089 | -3.467 | 0 | ||
Net Change in Cash | -17.855 | 37.175 | 15.054 | 18.629 | -3.275 |
Other Investing Cash Flow Items, Total | 3.518 | 47.202 | 64.386 | 52.76 | 13.436 |
Issuance (Retirement) of Stock, Net | 0.555 | 56.647 | 0.573 | 0.411 | 0.399 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Tang Capital Management, LLC | Hedge Fund | 14.5921 | 4024486 | 284145 | 2023-10-13 | MED |
BVF Partners L.P. | Hedge Fund | 12.7873 | 3526729 | 0 | 2023-08-10 | LOW |
Vellanki (Avanish) | Individual Investor | 9.2491 | 2550910 | -59618 | 2023-03-01 | |
Samsara BioCapital, LLC | Venture Capital | 7.3769 | 2034552 | -226100 | 2023-06-30 | LOW |
Boxer Capital, L.L.C. | Hedge Fund | 4.1777 | 1152212 | 0 | 2023-06-30 | LOW |
Berger (Franklin Milan) | Individual Investor | 3.6447 | 1005207 | 0 | 2023-03-01 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.3666 | 928499 | 855288 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.282 | 905171 | 24081 | 2023-06-30 | LOW |
Polen Capital Management, LLC | Investment Advisor/Hedge Fund | 2.6088 | 719513 | 0 | 2023-08-31 | LOW |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 2.3907 | 659349 | 656571 | 2023-06-30 | MED |
Millennium Management LLC | Hedge Fund | 2.1796 | 601143 | 556303 | 2023-06-30 | HIGH |
Doebele (Robert) | Individual Investor | 1.7289 | 476827 | 0 | 2023-03-01 | LOW |
Acuitas Investments LLC | Investment Advisor/Hedge Fund | 1.4839 | 409256 | 409256 | 2023-09-30 | HIGH |
Two Sigma Investments, LP | Hedge Fund | 1.3657 | 376670 | 298668 | 2023-06-30 | HIGH |
Western Standard, LLC | Hedge Fund | 1.2585 | 347089 | 347089 | 2023-06-30 | HIGH |
Ghost Tree Capital, LLC | Hedge Fund | 1.1784 | 325000 | 75000 | 2023-06-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.1728 | 323471 | 161578 | 2023-06-30 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 0.8652 | 238616 | 153534 | 2023-06-30 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8143 | 224571 | 169508 | 2023-06-30 | LOW |
Exchange Traded Concepts, LLC | Investment Advisor | 0.4616 | 127306 | 14494 | 2023-09-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Rain Therapeutics Inc. Company profile
About Rain Therapeutics Inc
Rain Therapeutics Inc. (Rain) is a clinical-stage precision oncology company. The Company is engaged in developing therapies that target oncogenic drivers. The Company's lead product candidate, RAIN-32 (milademetan) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2). It is being developed in patients with MDM2 amplified or overexpressed cancers. MDM2 inhibition is a treatment approach due to dose-limiting on-target hematologic toxicities. The initial development opportunity for RAIN-32 be in patients with MDM2-amplified tumors, beginning with well-differentiated/de-differentiated (WD/DD) liposarcoma (LPS) patients. Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. RAD inhibition leads to synthetic lethality in the DNA damage repair (DDR) pathway.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Rain Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased from $21.1M to $51.4M. Higher net loss reflects Research and development expense increase from $9.6M to $38.3M (expense), General and administrative expense increase from $3.3M to $10.1M (expense), Stock-based Compensation in R&D increase from $581K to $2.5M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
8000 Jarvis Avenue
Suite 204
NEWARK
CALIFORNIA 94560
US
Income Statement
- Annual
- Quarterly
News

A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023
XAU/USD Latest: Gold advances as weaker data weighs on US yields
Gold moves higher as softer economic data weighs on US yields and the dollar
13:43, 17 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com